Investigate Bioequivalence of Alpelisib Granule and Film-coated Tablet Formulation and the Food Effect of Alpelisib Granule Formulation in Adult Healthy Volunteers
NCT ID: NCT05195892
Last Updated: 2022-12-28
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1
33 participants
INTERVENTIONAL
2022-02-03
2022-11-09
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The study consists of a screening period followed by Periods 1, 2, and 3 and a safety follow-up. Randomization occurs at the beginning of Period 1, whereby every participant who passes the screening will be randomized to one of 6 sequences with 1:1:1:1:1:1 randomization ratio. Each sequence consists of a permutation of three treatments: A, B and C. The order of the sequence of the treatments (A, B, C) will be determined by randomization to the assigned sequence.
A total of 60 participants will be enrolled with approximately 10 participants per sequence, in order to obtain at least 48 evaluable participants for comparison of the granule formulation in fed status and the film-coated tablet formulation in fed status.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Sequence 1
Participants will receive a single oral dose of alpelisib film-coated tablet at 50 mg in fed state (treatment A) in period 1 followed by a single oral dose of alpelisib granule at 50 mg in fed state (treatment B) in period 2 and a single oral dose of alpelisib granule at 50 mg in fasted state (treatment C) in period 3.
Treatment A
Single oral dose of alpelisib film-coated tablet at 50 mg in fed state
Treatment B
Single oral dose of alpelisib granule at 50 mg in fed state
Treatment C
Single oral dose of alpelisib granule at 50 mg in fasted state
Sequence 2
Participants will receive a single oral dose of alpelisib granule at 50 mg in fed state (treatment B) in period 1 followed by a single oral dose of alpelisib granule at 50 mg in fasted state (treatment C) in period 2 followed by a single oral dose of alpelisib film-coated tablet at 50 mg in fed state (treatment A) in period 3.
Treatment A
Single oral dose of alpelisib film-coated tablet at 50 mg in fed state
Treatment B
Single oral dose of alpelisib granule at 50 mg in fed state
Treatment C
Single oral dose of alpelisib granule at 50 mg in fasted state
Sequence 3
Participants will receive a single oral dose of alpelisib granule at 50 mg in fasted state (treatment C) in period 1 followed by a single oral dose of alpelisib film-coated tablet at 50 mg in fed state (treatment A) in period 2 followed by a single oral dose of alpelisib granule at 50 mg in fed state (treatment B) in period 3.
Treatment A
Single oral dose of alpelisib film-coated tablet at 50 mg in fed state
Treatment B
Single oral dose of alpelisib granule at 50 mg in fed state
Treatment C
Single oral dose of alpelisib granule at 50 mg in fasted state
Sequence 4
Participants will receive a single oral dose of alpelisib granule at 50 mg in fasted state (treatment C) in period 1 followed by a single oral dose of alpelisib granule at 50 mg in fed state (treatment B) in period 2 followed by a single oral dose of alpelisib film-coated tablet at 50 mg in fed state (treatment A).
Treatment A
Single oral dose of alpelisib film-coated tablet at 50 mg in fed state
Treatment B
Single oral dose of alpelisib granule at 50 mg in fed state
Treatment C
Single oral dose of alpelisib granule at 50 mg in fasted state
Sequence 5
Participants will receive a single oral dose of alpelisib film-coated tablet at 50 mg in fed state (treatment A) in period 1 followed by a single oral dose of alpelisib granule at 50 mg in fasted state (treatment C) in period 2 followed by a single oral dose of alpelisib granule at 50 mg in fed state (treatment B).
Treatment A
Single oral dose of alpelisib film-coated tablet at 50 mg in fed state
Treatment B
Single oral dose of alpelisib granule at 50 mg in fed state
Treatment C
Single oral dose of alpelisib granule at 50 mg in fasted state
Sequence 6
Participants will receive a single oral dose of alpelisib granule at 50 mg in fed state (treatment B) in period 1 followed by a single oral dose of alpelisib film-coated tablet at 50 mg in fed state (treatment A) in period 2 followed by a single oral dose of alpelisib granule at 50 mg in fasted state (treatment C).
Treatment A
Single oral dose of alpelisib film-coated tablet at 50 mg in fed state
Treatment B
Single oral dose of alpelisib granule at 50 mg in fed state
Treatment C
Single oral dose of alpelisib granule at 50 mg in fasted state
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Treatment A
Single oral dose of alpelisib film-coated tablet at 50 mg in fed state
Treatment B
Single oral dose of alpelisib granule at 50 mg in fed state
Treatment C
Single oral dose of alpelisib granule at 50 mg in fasted state
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Female participants must be postmenopausal or not of child bearing potential.
* Participants must weigh 50 kg - 120 kg and have BMI= 18.0-30.0 kg/m2
* Participants should be in good health as determined by no clinically significant findings from the medical history, physical examination, vital signs, and ECG.
* Participant must have laboratory values (including fasting plasma glucose and HgbA1C) within the reference range at the local laboratory
* At screening, and at baseline visit of each Period, participant has vital signs which are within the protocol defined ranges
Exclusion Criteria
* Sexually active male participant with partner(s) of women of childbearing potential, UNLESS agree to comply with highly effective contraception AND use a condom
* Participant with
* significant illness, including infections, or hospitalization within the 30 days prior to dosing.
* diabetes mellitus or participants with fasting plasma glucose (FPG) levels \> 100 mg/dL or \>5.55 mmol/L.
* clinically significant risk of developing diabetes mellitus during the study
* Use of:
* tobacco products within 3 months prior to first dosing
* drug or alcohol abuse within 12 months prior to first dose
* alcohol within 48 hours prior to the dosing of each treatment period.
* any prescription or non-prescription, herbal medication, dietary supplements or vitamins during 14 days prior to dosing..
* History of :
* clinically significant hematologic, renal, endocrinologic, pulmonary, cardiovascular, hepatic, or allergic disease, medically documented. including uncontrolled hypertension, interstitial lung disease, or other causes of dyspnea, acute pancreatitis within 1 year of screening or past medical
* chronic pancreatitis.
* cardiac disease
* immunodeficiency diseases
* malignancy of any organ system carcinoma of the skin or in situ cervical cancer), within 5 years,
* erythema multiform (EM), Steven-Johnson-Syndrome (SJS) or Toxic Epidermal Necrolysis (TEN).
* history or presence of
* any surgical or medical condition which might significantly alter the absorption, distribution, metabolism or excretion of drugs.
* clinically significant ECG abnormalities or a family prolonged QT-interval syndrome.
* chronic infection with Hepatitis B (HBV) or Hepatitis C (HCV).
18 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Novartis Pharmaceuticals
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Novartis Pharmaceuticals
Role: STUDY_DIRECTOR
Novartis Pharmaceuticals
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Novartis Investigative Site
Belfast, Northern Ireland, United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Burmeister Getz E, Niglis S, Papadimitriou A, Statelova M, Ren X, Nakhla K, Sharaby S, Tariq M, Garbuio L, Bakhsh S. Predicting and Confirming Bioequivalence of Alpelisib Oral Granules and Tablets for Patients With PIK3CA-Related Disorders. AAPS PharmSciTech. 2025 Apr 30;26(5):121. doi: 10.1208/s12249-025-03109-4.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CBYL719F12101
Identifier Type: -
Identifier Source: org_study_id